Premium
Hospital readmission rates are similar between patients with mechanical versus bioprosthetic aortic valves
Author(s) -
Kilic Arman,
Bianco Valentino,
Gleason Thomas G.,
ArandaMichel Edgar,
Chu Danny,
Navid Forozan,
Althouse Andrew D.,
Sultan Ibrahim
Publication year - 2018
Publication title -
journal of cardiac surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 58
eISSN - 1540-8191
pISSN - 0886-0440
DOI - 10.1111/jocs.13781
Subject(s) - medicine , cardiology
Background The aim of this study was to evaluate hospital readmission rates and clinical outcomes between bioprosthetic (bAVR) and mechanical (mAVR) aortic valve replacements (AVR). Methods Adults aged 50 years or older undergoing isolated or concomitant AVR between 2011 and 2017 were included. The primary outcome was 5‐year hospital readmission. Multivariable logistic regression analysis was used to evaluate the risk‐adjusted impact of bAVR versus mAVR on outcomes. Results A total of 2981 patients were included: 406 (14%) mAVR and 2575 (86%) bAVR. Mean follow‐up was 2.9 ± 1.9 years. Operative mortality was comparable (4% bAVR vs 3% mAVR; P = 0.30). There was no risk‐adjusted difference in 30‐day (hazard ratio [HR] 1.32, P = 0.46), 1‐year (HR 1.17, P = 0.52), or 5‐year mortality (HR 0.99, P = 0.93). Aortic valve 5‐year reoperation rates were comparable (1%, P = 0.32). Risk‐adjusted hospital readmissions were similar at 30 days (14% vs 15%; P = 0.63), 1 year (30% vs 27%; P = 0.43), and 5 years (55% vs 53%; P = 0.83) in the bAVR and mAVR groups, respectively. Similar findings were demonstrated when evaluating readmissions for bleeding (5‐year readmission: 8% bAVR vs 10% mAVR; P = 0.36). Conclusions In this analysis of over 2900 AVRs, readmissions within 5 years were comparable between groups at approximately 50%, with patients being at highest risk in the early postdischarge period. Readmissions for bleeding constituted a minority of all readmissions for both cohorts.